卢克索利提尼布作为急性和慢性移植对宿主疾病的第一个后类固醇治疗方法
Mattia Algeri1,2, Marco Becilli1, Franco Locatelli1,3
1Department of Haematology/Oncology and Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.
Expert review of clinical immunology
|August 22, 2023
概括
鲁克索利提尼布在干细胞移植后提供了对抗类固醇耐药移植对宿主疾病 (SR-GvHD) 的有前途的二线治疗方法. 临床试验表明,当类固醇无效时,ruxolitinib可以改善结果.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 移植与宿主疾病 (GvHD) 是异性干细胞移植 (allo-HSCT) 的严重并发症.
- 类固醇是主要的治疗方法,但许多患者需要替代治疗类固醇耐药GvHD (SR-GvHD).
- 卢克索利提尼布正在成为SR-GvHD的关键治疗选择.
研究的目的:
- 审查ruxolitinib在GvHD中的疗效的生物和机械基础.
- 讨论SR-GvHD目前的治疗策略.
- 分析临床试验数据,包括在第三阶段试验中的优越性,用于SR-GvHD.在SR-GvHD中使用ruxolitinib.
主要方法:
- 在GvHD.HD中对ruxolitinib的生物特性和机制方面的文献综述.
- 讨论SR-GvHD现有的治疗选择.
- 对临床试验结果的分析,重点是两项III期随机试验,比较ruxolitinib与最好的可用疗法.
主要成果:
- 卢克索利提尼布在SR-GvHD的III期试验中证明了其优越性,超过了最好的可用疗法.
- 该药物的生物和机械性质支持其在管理GvHD中的作用.
- 卢克索利提尼布显著改善了SR-急性/慢性-GvHD.患者的治疗结果.
结论:
- 当皮质类固醇失效时,应考虑鲁克索利提尼布作为SR-GvHD的标准护理.
- 需要进一步的研究和更长的随访,以优化RS-GvHD与ruxolitinib的管理.
- 鲁克索利提尼布在治疗耐固醇性GvHD的治疗中取得了重大进展.
相关概念视频
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
150
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
150
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
01:26Kidney Transplant II: Surgical Procedure
36
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
36
01:22Bone Marrow Sampling and Transplants
360
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
360
01:29Drugs for Treatment of Ulcerative Colitis in IBD
173
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173